

=> s tiotropium

L1 5 TIOTROPIUM

=> dll

DL1 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d 11

L1 ANSWER 1 OF 5 REGISTRY COPYRIGHT 2002 ACS

RN 412010-61-8 REGISTRY

CN 3-Oxa-9-azoniatricyclo[3.3.1.0^{2,4}]nonane, 7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-, iodide,
(1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN **tiotropium iodide**

FS STEREOSEARCH


MF C19 H22 N O4 S2 . I

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

CRN (186691-13-4)

Relative stereochemistry.



● I⁻

6 REFERENCES IN FILE CA (1962 TO DATE)

6 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> d 2-5

L1 ANSWER 2 OF 5 REGISTRY COPYRIGHT 2002 ACS


RN 412010-60-7 REGISTRY

CN 3-Oxa-9-azoniatricyclo[3.3.1.0^{2,4}]nonane, 7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-, chloride,
(1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN **tiotropium chloride**
 FS STEREOSEARCH
 MF C19 H22 N O4 S2 . Cl
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL
 CRN (186691-13-4)

Relative stereochemistry.




● Cl⁻

6 REFERENCES IN FILE CA (1962 TO DATE)
 6 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L1 ANSWER 3 OF 5 REGISTRY COPYRIGHT 2002 ACS
 RN 411207-31-3 REGISTRY
 CN 3-Oxa-9-azoniatricyclo[3.3.1.0.2,4]nonane, 7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-, bromide, monohydrate, (1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN **Tiotropium bromide monohydrate**
 FS STEREOSEARCH
 MF C19 H22 N O4 S2 . Br . H2 O
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL
 CRN (186691-13-4)

Relative stereochemistry.




● Br⁻

● H₂O

8 REFERENCES IN FILE CA (1962 TO DATE)
8 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L1 ANSWER 4 OF 5 REGISTRY COPYRIGHT 2002 ACS
RN 186691-13-4 REGISTRY
CN 3-Oxa-9-azoniatricyclo[3.3.1.0^{2,4}]nonane, 7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-, (1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.a.)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN **Tiotropium**
FS STEREOSEARCH
MF C19 H22 N O4 S2
CI COM
SR CA
LC STN Files: ADISINSIGHT, BIOSIS, CA, CAPLUS, SYNTHLINE, TOXCENTER, USPATFULL


Relative stereochemistry.



35 REFERENCES IN FILE CA (1962 TO DATE)
8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
35 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L1 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2002 ACS
 RN 136310-93-5 REGISTRY
 CN 3-Oxa-9-azoniatricyclo[3.3.1.0^{2,4}]nonane, 7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-, bromide,
 (1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 3-Oxa-9-azatricyclo[3.3.1.0^{2,4}]nonane, 3-oxa-9-azoniatricyclo[3.3.1.0^{2,4}]nonane deriv.
 OTHER NAMES:
 CN BA 679BR
 CN Spiriva
 CN **Tiotropium bromide**
 FS STEREOSEARCH
 MF C19 H22 N O4 S2 . Br
 CI COM
 SR CA
 LC STN Files: ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CIN, DRUGNL, DRUGPAT, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PROMT, SYNTHLINE, TOXCENTER, USPATFULL
 (*File contains numerically searchable property data)
 CRN (186691-13-4)

Relative stereochemistry.



● Br⁻


54 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 54 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s beclomethasone
 L2 11 BECLOMETHASONE
 => s beclomethasone/cn
 L3 1 BECLOMETHASONE/CN
 => d 13

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

RN 4419-39-0 REGISTRY
 CN Pregna-1,4-diene-3,20-dione, 9-chloro-11,17,21-trihydroxy-16-methyl-,
 (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Pregna-1,4-diene-3,20-dione, 9-chloro-11.beta.,17,21-trihydroxy-16.beta.-
 methyl- (7CI, 8CI)
 OTHER NAMES:
 CN 9-Chloro-11.beta.,17,21-trihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-
 dione
 CN 9-Chloro-16.beta.-methylprednisolone
 CN Beclometasone
 CN **Beclomethasone**
 CN Becolvent
 FS STEREOSEARCH
 MF C22 H29 Cl O5
 CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CBNB,
 CEN,
 CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB,
 IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NIOSHTIC, PHAR, PROMT, SPECINFO,
 TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

341 REFERENCES IN FILE CA (1962 TO DATE)
 20 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 341 REFERENCES IN FILE CAPLUS (1962 TO DATE)
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> fil embase biosis medline caplus uspatfull

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

23.38

23.59

FILE 'EMBASE' ENTERED AT 20:43:53 ON 14 NOV 2002

COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 20:43:53 ON 14 NOV 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 20:43:53 ON 14 NOV 2002

FILE 'CAPLUS' ENTERED AT 20:43:53 ON 14 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 20:43:53 ON 14 NOV 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s beclomethasone or 4419-39-0/rn
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
L4 9446 BECLOMETHASONE OR 4419-39-0/RN

=> s tiotropium or 136310-93-5/rn or 186691-13-4/rn or 411207-31-3/rn or
412010-60-7/rn or 412010-61-8/rn
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
L5 337 TIOTROPIUM OR 136310-93-5/RN OR 186691-13-4/RN OR
411207-31-3/RN
OR 412010-60-7/RN OR 412010-61-8/RN

=> s l4 and l5
L6 44 L4 AND L5

=> s l6 and py<2000
2 FILES SEARCHED...
L7 8 L6 AND PY<2000

=> dup rem l7
PROCESSING COMPLETED FOR L7
L8 8 DUP REM L7 (0 DUPLICATES REMOVED)

=> d l8 1-8

L8 ANSWER 1 OF 8 USPATFULL
AN 2002:289804 USPATFULL
TI Dispenser with doses' counter
IN Rand, Paul Kenneth, Redhill, UNITED KINGDOM
Brand, Peter John, Royston, UNITED KINGDOM
Godfrey, James William, Hertfordshire, UNITED KINGDOM
PA Smithkline Beecham Corporation, Philadelphia, PA, United States (U.S.
corporation)
PI US 6474331 B1 20021105
WO 9856446 19980608 <--
AI US 2000-445658 20000331 (9)
WO 1998-EP3379 19980608
20000331 PCT 371 date
PRAI GB 1997-11889 19970610
GB 1997-21875 19971016
DT Utility
FS GRANTED
LN.CNT 633
INCL INCLM: 128/200.230

INCLS: 128/203.120
NCL NCLM: 128/200.230
NCLS: 128/203.120
IC [7]
ICM: A61M016-00
EXF 128/200.14; 128/200.23; 128/200.24; 128/200.25; 128/203.12; 128/203.15;
128/203.19-203.25; 128/200.18; 116/280; 116/307; 116/308; 116/311-315;
116/318; 116/319

L8 ANSWER 2 OF 8 USPATFULL
AN 2002:262040 USPATFULL
TI Medical aerosol formulations
IN Keller, Manfred, Bad Krozingen, GERMANY, FEDERAL REPUBLIC OF
Herzog, Kurt, Basel, SWITZERLAND
PA Jago Research AG, MuttENZ, SWITZERLAND (non-U.S. corporation)
PI US 6461591 B1 20021008
WO 9834595 19980813 <--
AI US 1999-355883 19990804 (9)
WO 1998-CH37 19980202
19990804 PCT 371 date
PRAI CH 1997-248 19970205
DT Utility
FS GRANTED
LN.CNT 932
INCL INCLM: 424/045.000
INCLS: 514/177.000; 514/263.340; 514/374.000; 514/471.000; 514/490.000;
514/506.000; 514/646.000; 514/693.000; 514/699.000; 514/721.000;
514/728.000; 514/730.000; 514/731.000; 514/736.000; 514/738.000;
514/772.000; 514/957.000; 514/958.000
NCL NCLM: 424/045.000
NCLS: 514/177.000; 514/263.340; 514/374.000; 514/471.000; 514/490.000;
514/506.000; 514/646.000; 514/693.000; 514/699.000; 514/721.000;
514/728.000; 514/730.000; 514/731.000; 514/736.000; 514/738.000;
514/772.000; 514/957.000; 514/958.000
IC [7]
ICM: A61K009-12
ICS: A61K031-00; A61K047-00
EXF 424/45; 514/957; 514/958; 514/975; 514/177; 514/263.34; 514/374;
514/471; 514/490; 514/506; 514/646; 514/643; 514/699; 514/721; 514/728;
514/730; 514/731; 514/736; 514/738; 514/772
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 8 USPATFULL
AN 2002:200714 USPATFULL
TI Dispenser with doses' counter
IN Rand, Paul Kenneth, Redhill, UNITED KINGDOM
Brand, Peter John, Royston, UNITED KINGDOM
Godfrey, James William, Hertfordshire, UNITED KINGDOM
Bonney, Stanley George, Hertfordshire, UNITED KINGDOM
PA Smithkline Beecham Corporation, Philadelphia, PA, United States (U.S.
corporation)
PI US 6431168 B1 20020813
WO 9856444 19981217 <--
AI US 2000-445673 20000313 (9)
WO 1998-EP3377 19980608
20000313 PCT 371 date
PRAI GB 1997-11889 19970610
GB 1997-21875 19971016
DT Utility
FS GRANTED

LN.CNT 747
 INCL INCLM: 128/200.230
 INCLS: 128/203.120; 128/200.180; 128/200.140; 128/203.230
 NCL NCLM: 128/200.230
 NCLS: 128/200.140; 128/200.180; 128/203.120; 128/203.230
 IC [7]
 ICM: A61M016-00
 EXF 128/203.12; 128/200.18; 128/200.23; 128/200.14; 128/203.15; 128/203.19;
 128/203.23; 222/38; 222/36; 222/162
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 8 USPATFULL
 AN 2002:62596 USPATFULL
 TI Dispenser with doses counter
 IN Rand, Paul Kenneth, Redhill, UNITED KINGDOM
 Brand, Peter John, Royston, UNITED KINGDOM
 Godfrey, James William, Hertfordshire, UNITED KINGDOM
 PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S.
 corporation)
 PI US 6360739 B1 20020326
 WO 9856445 19981217 <--
 AI US 2000-445659 20000331 (9)
 WO 1998-EP3378 19980608
 20000331 PCT 371 date
 PRAI GB 1997-11889 19970610
 GB 1997-21875 19971016

DT Utility
 FS GRANTED
 LN.CNT 642
 INCL INCLM: 128/200.230
 INCLS: 128/203.120; 128/200.180; 128/200.140; 128/203.230
 NCL NCLM: 128/200.230
 NCLS: 128/200.140; 128/200.180; 128/203.120; 128/203.230
 IC [7]
 ICM: A61M016-00
 EXF 128/203.12; 128/200.18; 128/200.23; 128/200.14; 128/203.15; 128/203.19;
 128/203.23; 222/38; 222/36; 222/162

L8 ANSWER 5 OF 8 USPATFULL
 AN 2001:42141 USPATFULL
 TI Nitrosated and nitrosylated compounds, and compositions and their use
 for treating respiratory disorders
 IN Garvey, David S., Dover, MA, United States
 Letts, L. Gordon, Dover, MA, United States
 Renfro, H. Burt, Wellesley, MA, United States
 Richardson, Stewart K., Ashford, CT, United States
 PA NitroMed, Inc., Bedford, MA, United States (U.S. corporation)
 PI US 37116 E1 20010327
 US 5824669 19981020 (Original) <--
 AI US 1998-219476 19981223 (9)
 US 1996-620882 19960322 (Original)
 DT Reissue
 FS Granted
 LN.CNT 1916
 INCL INCLM: 514/174.000
 INCLS: 514/178.000; 514/179.000; 540/063.000; 540/066.000; 552/565.000;
 552/566.000; 552/575.000
 NCL NCLM: 514/174.000
 NCLS: 514/178.000; 514/179.000; 540/063.000; 540/066.000; 552/565.000;
 552/566.000; 552/575.000

IC [7]
ICM: A61K031-58
ICS: C07J005-00; C07J007-00; C07J031-00; C07J071-00
EXF 514/174; 514/178; 514/179; 540/63; 540/66; 552/565; 552/566; 552/575
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2002 ACS
AN 1998:548517 CAPLUS
DN 129:166237
TI Fluorocarbon propellants for medical aerosol formulations
IN Keller, Manfred; Herzog, Kurt
PA Jago Pharma A.-G., Switz.
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9834595	A1	19980813	WO 1998-CH37	19980202 <--
	W: AU, CA, JP, NO, NZ, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE	AU 9856496	A1	19980826	AU 1998-56496	19980202 <--
	AU 718967	B2	20000504		
	EP 1014943	A1	20000705	EP 1998-900837	19980202
	EP 1014943	B1	20020619		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI	JP 2001511160	T2	20010807	JP 1998-533479	19980202
	AT 219355	E	20020715	AT 1998-900837	19980202
	ZA 9800937	A	19980806	ZA 1998-937	19980205 <--
	NO 9903773	A	19991004	NO 1999-3773	19990804 <--
	US 6461591	B1	20021008	US 1999-355883	19990804
PRAI	CH 1997-248	A	19970205		
	WO 1998-CH37	W	19980202		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 8 USPATFULL
AN 1998:128257 USPATFULL
TI Nitrosated and nitrosylated compounds and compositions and their use
for

treating respiratory disorders
IN Garvey, David S., Dover, MA, United States
Letts, L. Gordon, Dover, MA, United States
Renfro, H. Burt, Wellesley, MA, United States
Richardson, Stewart K., Ashford, CT, United States
PA NitroMed, Inc., Bedford, MA, United States (U.S. corporation)
PI US 5824669 19981020 <--
AI US 1996-620882 19960322 (8)
DT Utility
FS Granted
LN.CNT 1812
INCL INCLM: 514/174.000
INCLS: 514/178.000; 514/179.000; 540/063.000; 540/066.000; 552/572.000;
552/573.000; 552/575.000; 552/565.000; 552/566.000
NCL NCLM: 514/174.000
NCLS: 514/178.000; 514/179.000; 540/063.000; 540/066.000; 552/565.000;
552/566.000; 552/572.000; 552/573.000; 552/575.000

IC [6]
ICM: A61K031-58
ICS: C07J071-00; C07J007-00; C07J005-00
EXF 552/572; 552/573; 552/575; 552/565; 552/566; 540/63; 540/66; 514/174;
514/178; 514/179
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 8 USPATFULL
AN 1998:98932 USPATFULL ,
TI DHA-pharmaceutical agent conjugates of taxanes
IN Shashoua, Victor E., Brookline, MA, United States
Swindell, Charles S., Merion, PA, United States
Webb, Nigel L., Bryn Mawr, PA, United States
Bradley, Matthews O., Laytonsville, MD, United States
PA Neuromedica, Inc., Conshohocken, PA, United States (U.S. corporation)
PI US 5795909 19980818 <--
AI US 1996-651312 19960522 (8)
DT Utility
FS Granted
LN.CNT 2451
INCL INCLM: 514/449.000
INCLS: 514/549.000
NCL NCLM: 514/449.000
NCLS: 514/549.000
IC [6]
ICM: A61K031-335
ICS: A61K031-22
EXF 514/449; 514/549
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 18 1-8 ab kwic

L8 ANSWER 1 OF 8 USPATFULL
AB There is provided a dispenser suitable for dispensing medicament,
particularly medicament for use in the treatment of respiratory
disorders. The dispenser comprises a housing (1) having a support (5);
a
container (2), locatable within said housing (1), having an outlet (3),
wherein said container (2) dispenses through said outlet (3) in
response
to movement of the container (2), relative to the housing (1); and an
actuation indicator having an indexing mechanism (13, 43) actuatable by
movement of the container (2) relative to the housing (1). A couple
mechanism (13, 43) is provided which couples the indexing mechanism
(13,
43) to the container (2) to compensate for any variation in
pre-actuation positionings of the indexing mechanism and container.
PI US 6474331 B1 20021105
WO 9856446 19980608 <--
DETD . . . antiallergics, e.g., cromoglycate, ketotifen or nedocromil;
antiinfectives e.g., cephalosporins, penicillins, streptomycin,
sulphonamides, tetracyclines and pentamidine; antihistamines, e.g.,
methapyrilene; anti-inflammatories, e.g., **beclomethasone**
dipropionate, fluticasone propionate, flunisolide, budesonide,
rofleponide, mometasone furoate or triamcinolone acetonide;
antitussives, e.g., noscapine; bronchodilators, e.g., albuterol,
salmeterol, ephedrine, adrenaline, . . . fenoterol, formoterol,
isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine,
pirbuterol, reproterol, rimiterol, terbutaline, isoetharine,

tulobuterol, or (-)-4-amino-3,5-dichloro-.alpha.-[[[6-[2-(2-pyridinyl)ethoxy]hexyl)methyl]benzenemethanol; diuretics, e.g., amiloride; anticholinergics, e.g., ipratropium, **tiotropium**, atropine or oxitropium; hormones, e.g., cortisone, hydrocortisone or prednisolone; xanthines, e.g., aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; therapeutic proteins. . . .

DETD . . . or the sulphate salt) or salmeterol (e.g., as the xinafoate salt) in combination with an antiinflammatory steroid such as a **beclomethasone** ester (e.g., the dipropionate) or a fluticasone ester (e.g., the propionate).

CLM What is claimed is:
 12. The drug product of claim 1, wherein the medicament is a member selected from the group consisting of **beclomethasone**, fluticasone, albuterol, salmeterol, ipratropium, (-)-4-amino-3,5-dichloro-.alpha.-[[[6-[2-(2-pyridinyl)ethoxy]hexyl)methyl]benzenemethanol and salts, esters or solvates thereof.

16. The drug product of claim 12, wherein the medicament is **beclomethasone** dipropionate.

L8 ANSWER 2 OF 8 USPATFULL

AB A pressure-liquefied propellant mixture for aerosols, comprising a fluorinated alkane, in particular 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane, and carbon dioxide, makes possible an improvement of the wetting properties of pharmaceutically active compounds, with which the formulation problems existing with hydrofluoroalkanes in relation to suspension as well as solution aerosols can be overcome and thus improved medicinal aerosol formulations can be obtained. With the aid of carbon dioxide, it is also possible to specifically influence the pressure and thus the particle size distribution and also by displacement of oxygen from the hydrofluoroalkanes to improve the storage stability of oxidation-sensitive active compounds.

PI US 6461591 B1 20021008
 WO 9834595 19980813 <--

DETD corticoids such as **beclomethasone**, betamethasone, ciclomethasone, dexamethasone, triamcinolone, budesonide, butixocort, ciclesonide, fluticasone, flunisolide, icomethasone, mometasone, tixocortol, loteprednol etc.,

DETD Using the propellant system according to the invention, it is possible to produce, for example, a **beclomethasone** metered aerosol which in comparison to a CFC-containing commercial product (Becotide.RTM., Glaxo Pharmaceuticals, Great Britain) has a far better dosage. . . . is approximately halved and that in the "sample induction port" (artificial oropharynx) is reduced from about 50% to 20%. The **beclomethasone** formulation according to the invention thus makes it possible to design the metered aerosol more advantageously in relation to several. . . .

DETD a) 2.5 g of **beclomethasone** dipropionate are weighed into a pressure addition vessel and dissolved with stirring in 55 g of ethanol, in which 0.25. . . .

DETD impacter according to USP 23 using puff Nos. 11-30 and 178-197 (3 canisters each, manual actuation). In all cases, the **beclomethasone** dipropionate was determined by means of HPLC and UV measurement at 230 nm. The mass median aerodynamic diameter MMAD was.

DETD b) In the same manner as in paragraph a), a solution aerosol formulation

of **beclomethasone** dipropionate was prepared in HFA 227, ethanol and oleic acid, but the pressure was adjusted to 4.5 bar (20.degree. C.). . .

DETD 15.6 g of **beclomethasone** dipropionate are dissolved in 811 g of ethanol which contains 3 g of oleic acid. The clear solution is mixed. . .

CLM What is claimed is:

. . . aerosol formulation according to claim 1, wherein the pharmaceutically active compound is a corticoid selected from the group consisting of **beclomethasone**, betamethasone, ciclomethasone, dexamethasone, triamcinolone, budesonide, butixocort, ciclesonide, fluticasone, flunisolide, icomethasone, mometasone, tixocortol, loteprednol, and pharmaceutically acceptable salts thereof.

. . . does inhaler according to claim 10, wherein the pharmaceutically active compound is a corticoid selected from the group consisting of **beclomethasone**, betamethasone, ciclomethasone, dexamethasone, triamcinolone, budesonide, butixocort, ciclesonide, fluticasone, flunisolide, icomethasone, mometasone, tixocortol, loteprednol, and pharmaceutically acceptable salts thereof.

IT 50-02-2, Dexamethasone 50-28-2, Estradiol, biological studies 50-56-6, Oxytocin, biological studies 50-67-9, Serotonin, biological studies 51-34-3, Scopolamine 51-43-4, Epinephrine 51-55-8, Atropine, biological studies 57-27-2, Morphine, biological studies 57-42-1, Pethidine 76-25-5, Triamcinolone acetone 76-42-6, Oxycodone 76-99-3, Methadone 113-15-5, Ergotamine 119-13-1, .delta.-Tocopherol 124-94-7, Triamcinolone 302-41-0, Piritramide 359-83-1, Pentazocine 361-37-5, Methysergide 378-44-9, Betamethasone 437-38-7, Fentanyl 456-59-7, Cycloclatrate 469-62-5, Dextropropoxyphene 561-27-3, Heroin 586-06-1, Orciprenaline 596-51-0, Glycopyrrolate 1679-76-1, Drofenine 3215-70-1, Hexoprenaline 3385-03-3, Flunisolide 3703-79-5, Bamethan 4419-39-0, Beclomethasone 4647-20-5, Icomethasone 5534-09-8, Beclomethasone dipropionate 5633-20-5, Oxybutynin 7182-53-8, N-Butylscopolamine 7683-59-2, Isoprenaline 9002-62-4, Prolactin, biological studies 9002-64-6, Parathyrin 9002-71-5, Thyrotropin 9002-72-6, Somatotropin 9002-79-3, Melanotropin 9004-10-8, Insulin, biological studies 9005-49-6, Heparin, biological studies 9007-12-9, Calcitonin 9007-92-5, Glucagon, biological studies 10405-02-4, Trospium chloride 10539-19-2, Moxaverine 11000-17-2, Vasopressin 11096-26-7, Erythropoietin 13010-47-4, Lomustine 13392-18-2, Fenoterol 13669-70-0, Nefopam 16110-51-3, Cromoglycic acid 18559-94-9, Salbutamol 20594-83-6, Nalbuphine 22254-24-6,

Ipratropium

bromide 23031-25-6, Terbutaline 27203-92-5, Tramadol 30286-75-0, Oxitropium bromide 37148-27-9, Clenbuterol 41570-61-0, Tulobuterol 43229-80-7, Formoterol fumarate 51333-22-3, Budesonide 51931-66-9, Tilidine 52485-79-7, Buprenorphine 54063-54-6, Reproterol 61951-99-3, Tixocortol 69049-73-6, Nedocromil 73573-87-2, Formoterol 76596-57-1, Broxaterol 80474-14-2, Fluticasone propionate

81732-65-2,

Bambuterol 85637-73-6, Atriopeptin 86022-88-0, Cyclomethasone 89365-50-4, Salmeterol 90566-53-3, Fluticasone 103628-46-2, Sumatriptan 105102-22-5, Mometasone 111406-87-2, Zileuton 120815-74-9, Butixocort 126544-47-6, Ciclesonide 129260-79-3, Loteprednol 136310-93-5, Tiotropium bromide 139264-17-8,

Zolmitriptan

(fluorocarbon propellants for medical aerosol formulations)

L8 ANSWER 3 OF 8 USPATFULL

AB There is provided a dispenser suitable for dispensing medicament, particularly medicament for use in the treatment of respiratory disorders. The dispenser comprises a housing (1) having a support (5);

a container (2), locatable within said housing (1), having an outlet member, wherein said container (2) is movable relative to the housing (1) to enable dispensing therefrom and said outlet member is

connectable

with said support (5) to prevent relative movement there-between; and a dose indicator (13, 43), locatable within said housing (1). The container (2) and dose indicator (13, 43) are reversably removable from the housing (1) as a single unit.

PI US 6431168 B1 20020813

WO 9856444 19981217

<--

DETD . . . antiallergics, e.g., cromoglycate, ketotifen or nedocromil; antiinfectives e.g., cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, e.g., methapyrilene; anti-inflammatories, e.g., **beclomethasone** dipropionate, fluticasone propionate, flunisolide, budesonide, rofleponide, mometasone furoate or triamcinolone acetate; antitussives, e.g., noscapine; bronchodilators, e.g., albuterol, salmeterol, ephedrine, adrenaline, . . . formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, terbutaline, isoetharine, tulobuterol, or (-)-4-amino-3,5-dichloro-.alpha.-[[[6-[2-(2-pyridinyl)ethoxy]hexyl)methyl]benzenemethanol; diuretics, e.g., amiloride; . anticholinergics, e.g., ipratropium, **tiotropium**, atropine or oxitropium; hormones, e.g., cortisone, hydrocortisone or prednisolone; xanthines, e.g., aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; therapeutic proteins. . .

DETD . . . or the sulphate salt) or salmeterol (e.g., as the xinafoate salt) in combination with an antiinflammatory steroid such as a **beclomethasone** ester (e.g., the dipropionate) or a fluticasone ester (e.g., the propionate).

CLM What is claimed is:

22. The drug product of claim 17, wherein the medicament is selected from the group consisting of **beclomethasone**, fluticasone, flunisolide, budesonide, rofleponide, mometasone, triamcinolone, noscapine, albuterol, salmeterol, ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, terbutaline, **tiotropium**, ipratropium, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, isoetharine, tulobuterol, (-)-4-amino-3,5-dichloro-.alpha.-[[[6-[2-(2-pyridinyl)ethoxy]hexyl)methyl]benzenemethanol, esters, solvates and salts thereof, and combinations thereof.

26. The drug product of claim 17, wherein the medicament is **beclomethasone** dipropionate.

L8 ANSWER 4 OF 8 USPATFULL

AB There is provided a dispenser suitable for dispensing medicament, particularly medicament for use in the treatment of respiratory disorders. The dispenser comprises a housing (1) having a support (5),

a container (2), locatable within said housing (1), having an outlet (3),

wherein said container (2) dispenses through said outlet (3) in response to movement of the container (2) relative to the housing (1) and an actuation indicator having an indexing mechanism (13,43) actuable by movement of the container (2) relative to the housing (1). The indexing mechanism (13, 43) includes a coupling element to compensate for excess movement of the container (2) relative to the housing (1).

PI US 6360739 B1 20020326
WO 9856445 19981217

<--

DETD . . . antiallergics, e.g., cromoglycate, ketotifen or nedocromil; antiinfectives e.g., cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, e.g., methapyrilene; anti-inflammatories, e.g., **beclomethasone** dipropionate, fluticasone propionate, flunisolide, budesonide, rofleponide, mometasone furoate or triamcinolone acetonide; antitussives, e.g., noscapine; bronchodilators, e.g., albuterol, salmeterol, ephedrine, adrenaline, . . . isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, terbutaline, isoetharine, tulobuterol, or (-)-4-amino-3,5-dichloro-.alpha.-[[[6-[2-(2-pyridinyl)ethoxy] hexyl]methyl] benzenemethanol; diuretics, e.g., amiloride; anticholinergics, e.g., ipratropium, **tiotropium**, atropine or oxitropium; hormones, e.g., cortisone, hydrocortisone or prednisolone; xanthines, e.g., aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; therapeutic proteins. . .

DETD . . . or the sulphate salt) or salmeterol (e.g., as the xinafoate salt) in combination with an antiinflammatory steroid such as a **beclomethasone** ester (e.g., the dipropionate) or a fluticasone ester (e.g., the propionate).

CLM What is claimed is:

12. The drug product of claim 11, wherein the medicament is selected from the group consisting of **beclomethasone**, fluticasone, flunisolide, budesonide, rofleponide, mometasone, triamcinolone, noscapine, albuterol, salmeterol, ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, terbutaline, **tiotropium**, ipratropium, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, isoetharine, tulobuterol, (-)-4-amino-3,5-dichloro-.alpha.-{[(6-[2-(2-pyridinyl)ethoxy]hexyl)methyl] benzenemethanol, esters, solvates and salts thereof, and combinations thereof.

16. The drug product of claim 12, wherein the medicament is **beclomethasone** dipropionate.

L8 ANSWER 5 OF 8 USPATFULL

AB Disclosed are (i) compounds of a steroid, a .beta.-agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO.sub.2 group or a group which stimulates endogenous production of NO or EDRF in vivo;

(ii) compositions of steroids, .beta.-agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted

with at least one NO or NO.sub.2 moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO.sup.+) or nitroxyl (NO.sup.-), or as the neutral species, nitric oxide (NO.circle-solid.) or that stimulates endogenous

production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders. ##STR1##

PI US 37116 E1 20010327

US 5824669 19981020 (Original) <--

SUMM . . . pirbuterol, rimiterol, clenbuterol, bitolterol and repreterol, adrenalin, isoproterenol, ephedrine, orciprenlaine, fenoterol and isoetharine); anticholinergic agents (such as atropine, ipratropium, flutropium, **tiotropium** and rispenzepine) and mast cell stabilizers (chromolyn and nedocromil). Selective .beta. agonists have recently been developed with fewer cardiotoxic side. . .

SUMM . . . asthmaticus. Nonetheless, the use of inhaled corticosteroids for the treatment of bronchial asthma has increased in recent years. Most frequently **beclomethasone** dipropionate, triamcinolone acetonide or flunisolide can be used to reduce or replace oral corticosteroid therapy, particularly in the treatment of. . .

DETD . . . contemplated .beta.-agonists include salmeterol, albuterol, metaproterenol, terbutaline, pitbuterol, rimiterol, clenbuterol, bitoterol and reproterol. Examples of contemplated anticholinergics include ipratropium, flutropium, **tiotropium** and rispenzepine. Examples of contemplated mast cell stabilizers include cromolyn and nedocromil. Examples of contemplated PDE inhibitors include filaminast, denbufyllene. . .

L8 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2002 ACS

AB A pressure-liquefied propellant mixt. for aerosols comprising a fluoridated alkane [esp. 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane (HFA 227)] and CO2 improves the wetting properties for pharmaceutical active substances, whereby existing formulation problems with hydrofluoroalkanes in suspension and soln. aerosols can be overcome and improved medical aerosol formulations can be obtained. By using CO2, the pressure and hence the particle size distribution can be influenced in a targeted manner, and by removing O2 from the hydrofluoroalkanes the stability during storage of oxidn.-sensitive active substances can be improved. Thus, 1.5 kg HFA 227 was gassed with CO2 and added at 6.5 bar and 20.degree. to a soln. of **beclomethasone** dipropionate 2.5 and oleic acid 0.25 in EtOH 55 g in a pressurized vessel; the mixt. was dispensed into A1 aerosol canisters. The mean aerodynamic particle diam. and fine particle dose

per stroke of the dosing valve were .apprx.1.3 .mu.m and 61.5 .mu.g, resp., immediately after filling the canisters; after 6 mo storage at 30.degree. and 70% relative humidity, these values were .apprx.1.3 .mu.m and 71.8 .mu.g, resp.

PI WO 9834595 A1 **19980813**

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9834595	A1	19980813	WO 1998-CH37	19980202 <--
W: AU, CA, JP, NO, NZ, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				

SE

AU 9856496	A1	19980826	AU 1998-56496	19980202 <--
AU 718967	B2	20000504		
EP 1014943	A1	20000705	EP 1998-900837	19980202
EP 1014943	B1	20020619		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,

FI

JP 2001511160	T2	20010807	JP 1998-533479	19980202
AT 219355	E	20020715	AT 1998-900837	19980202
ZA 9800937	A	19980806	ZA 1998-937	19980205 <--
NO 9903773	A	19991004	NO 1999-3773	19990804 <--

US 6461591 B1 20021008 US 1999-355883 19990804

AB . . . Thus, 1.5 kg HFA 227 was gassed with CO2 and added at 6.5 bar
and

20.degree. to a soln. of **beclomethasone** dipropionate 2.5 and
oleic acid 0.25 in EtOH 55 g in a pressurized vessel; the mixt. was
dispensed into Al. . .

IT 50-02-2, Dexamethasone 50-28-2, Estradiol, biological studies
50-56-6,

Oxytocin, biological studies 50-67-9, Serotonin, biological studies
51-34-3, Scopolamine 51-43-4, Epinephrine 51-55-8, Atropine,
biological studies 57-27-2, Morphine, biological studies 57-42-1,
Pethidine 76-25-5, Triamcinolone acetone 76-42-6, Oxycodone
76-99-3, Methadone 113-15-5, Ergotamine 119-13-1, .delta.-Tocopherol
124-94-7, Triamcinolone 302-41-0, Piritramide 359-83-1, Pentazocine
361-37-5, Methysergide 378-44-9, Betamethasone 437-38-7, Fentanyl
456-59-7, Cyclandelate 469-62-5, Dextropropoxyphene 561-27-3, Heroin
586-06-1, Orciprenaline 596-51-0, Glycopyrrolate 1679-76-1, Drofenine
3215-70-1, Hexoprenaline 3385-03-3, Flunisolide 3703-79-5, Bamethan
4419-39-0, Beclomethasone 4647-20-5, Icomethasone
5534-09-8, **Beclomethasone** dipropionate 5633-20-5, Oxybutynin
7182-53-8, N-Butylscopolamine 7683-59-2, Isoprenaline 9002-62-4,
Prolactin, biological studies 9002-64-6, Parathyrin 9002-71-5,
Thyrotropin 9002-72-6, Somatotropin 9002-79-3, Melanotropin
9004-10-8, Insulin, biological studies 9005-49-6, Heparin, biological
studies 9007-12-9, Calcitonin 9007-92-5, Glucagon, biological studies
10405-02-4, Trosipium chloride 10539-19-2, Moxaverine 11000-17-2,
Vasopressin 11096-26-7, Erythropoietin 13010-47-4, Lomustine
13392-18-2, Fenoterol 13669-70-0, Nefopam 16110-51-3, Cromoglycic
acid

18559-94-9, Salbutamol 20594-83-6, Nalbuphine 22254-24-6, Ipratropium
bromide 23031-25-6, Terbutaline 27203-92-5, Tramadol 30286-75-0,
Oxitropium bromide 37148-27-9, Clenbuterol 41570-61-0, Tulobuterol
43229-80-7, Formoterol fumarate 51333-22-3, Budesonide 51931-66-9,
Tilidine 52485-79-7, Buprenorphine 54063-54-6, Reproterol
61951-99-3, Tixocortol 69049-73-6, Nedocromil 73573-87-2, Formoterol
76596-57-1, Broxaterol 80474-14-2, Fluticasone propionate 81732-65-2,
Bambuterol 85637-73-6, Atriopeptin 86022-88-0, Cyclomethasone
89365-50-4, Salmeterol 90566-53-3, Fluticasone 103628-46-2,
Sumatriptan 105102-22-5, Mometasone 111406-87-2, Zileuton
120815-74-9, Butixocort 126544-47-6, Ciclesonide 129260-79-3,
Loteprednol **136310-93-5, Tiotropium** bromide
139264-17-8, Zolmitriptan

RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study);
USES
(Uses)
(fluorocarbon propellants for medical aerosol formulations)

L8 ANSWER 7 OF 8 USPATFULL

AB Disclosed are (i) compounds of a steroid, a .beta.-agonist, an
anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE)
inhibitor directly or indirectly linked to a NO or NO.sub.2 group or a
group which stimulates endogenous production of NO or EDRF in vivo;
(ii)
compositions of steroids, .beta.-agonists, anticholinergics, mast cell
stabilizers and PDE inhibitors, which can optionally be substituted
with
at least one NO or NO.sub.2 moiety or a group which stimulates
endogenous production of NO or EDRF in vivo, and a compound that

donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO.sup.+) or nitroxyl (NO.sup.-), or as the neutral species, nitric oxide (NO.circle-solid.) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.

PI US 5824669 19981020 <--
SUMM . . . pirbuterol, rimiterol, clenbuterol, bitolterol and repreterol, adrenalin, isoproterenol, ephedrine, orciprenlaine, fenoterol and isoetharine); anticholinergic agents (such as atropine, ipratropium, flutropium, **tiotropium** and rispenzepine) and mast cell stabilizers (chromolyn and nedocromil). Selective .beta. agonists have recently been developed with fewer cardiotoxic side. . . .
SUMM . . . asthmaticus. Nonetheless, the use of inhaled corticosteroids for the treatment of bronchial asthma has increased in recent years. Most frequently **beclomethasone** dipropionate, triamcinolone acetonide or flunisolide can be used to reduce or replace oral corticosteroid therapy, particularly in the treatment of. . . .
DETD . . . contemplated .beta.-agonists include salmeterol, albuterol, metaproterenol, terbutaline, pitbuterol, rimiterol, clenbuterol, bitoterol and reproterol. Examples of contemplated anticholinergics include ipratropium, flutropium, **tiotropium** and rispenzepine. Examples of contemplated mast cell stabilizers include cromolyn and nedocromil. Examples of contemplated PDE inhibitors include fluticasone, denbufyllene. . . .

L8 ANSWER 8 OF 8 USPATFULL

AB The invention provides conjugates of cis-docosahexaenoic acid and taxanes useful in treating cell proliferative disorders. Conjugates of paclitaxel and docetaxel are preferred.

PI US 5795909 19980818 <--

DETD Glucocorticoid: Amcinonide; **Beclomethasone** Dipropionate; Betamethasone; Betamethasone Acetate; Betamethasone Benzoate; Betamethasone Dipropionate; Betamethasone Sodium Phosphate; Betamethasone Valerate; Carbenoxolone Sodium; Clocortolone Acetate; Clocortolone Pivalate; Cloprednol;. . . .
DETD . . . thiocoraline; thiofedrine; thiomarinol; thioperamide; thyroid stimulating hormone; tiagabine; tianeptine; tiapafant; tibolone; ticlopidine; tienoxolol; tilisolol; tilnoprofen arbamel; tiludronic acid; tinzaparin sodium; **tiotropium** bromide; tipredane; tiqueside; tirandalydigin; tirapazamine; tirilazad; tirofiban; tiropramide; topsentin; torasemide; toremifene; tosufloxacin; trafermin;
trandolapril; traxanox; tretinoin; tretinoin tocoferil; triacetyluridine; tricaprillin;. . . .

=>